Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of Shigella flexneri 2a InvaplexAR
NCT02445963Phase 1Completed
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Oct 2015
- Primary completion
- May 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of Shigella flexneri 2a InvaplexAR in shigellosis and bacillary dysentery (4 arms), sponsored by U.S. Army Medical Research and Development Command. Primary endpoints: Number of Treatment Related Adverse Events at 166 days and Antibody Titers Against IgG and IgA Immunizing Antigens at Day 56. Started Oct 2015; status: completed.
02
Drugs
Shigella flexneri 2a InvaplexAR
03
Conditions
shigellosisbacillary dysentery
Beyond the preview
Go deeper on NCT02445963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02445963.